Arimoclomol for Treating Glucocerebrosidase Associated Disorders
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 11,253,505 | Arimoclomol for Treating Glucocerebrosidase Associated Disorders In force · Medium confidence | Zevra Denmark A/S | In force | Medium confidence | ||
| Application 17/574,239 | Arimoclomol for Treating Glucocerebrosidase Associated Disorders Abandoned Abandoned Dec 12, 2025 | Zevra Denmark A/S | Abandoned | Abandoned Dec 12, 2025 | ||
| Application 19/315,132 | Arimoclomol for Treating Glucocerebrosidase Associated Disorders Pending Not granted | Zevra Denmark A/S | Pending | Not granted |
3 of 3 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
1 of these is in force and held by Zevra Denmark A/S.
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.